Bullfrog AI

BFRG

Market cap $18.3M

BullFrog AI team will be available to discuss its end-to-end drug discovery and development workflow at booth 2957 BullFrog AI team will be available to discuss its end-to-end drug discovery and development workflow at booth 2957

GAITHERSBURG, Md., April 13, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (Nasdaq: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence and machine learning to turn complex biomedical data into actionable insights, today issued the following letter to shareholders from Vin Singh, Founder and CEO: Dear Fellow Shareholders, BullFrog AI enters the second quarter of 2026 well-capitalized, at commercial stage, and in active discussions with consequential pharmaceutical and biotechnology organizations.

BullFrog said the agreement will utilize its end-to-end analytical AI platform to accelerate the partner's drug discovery and clinical development program for MDD.

Bullfrog AI Inc more than doubled on Mar. 30 after announcing a landmark commercial agreement with a “top 5” pharma leader to identify novel therapeutic targets for Major Depressive Disorder. In its press release, BFRG said the pharmaceutical giant has agreed to use its proprietary bfLEAP® platform – providing high-profile validation of its machine-leaning-driven drug discovery tech.

Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) shares shot up 134% to $1.19 after the company announced a commercial agreement with a top five global pharmaceutical company to apply its proprietary bfLEAP platform to identify and prioritize novel drug targets in major depressive disorder.

GAITHERSBURG, Md., March 30, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, today announced a commercial agreement with a top 5 global pharmaceutical company in 2025 by revenue (“Customer”), to apply the Company's proprietary bfLEAP® platform to identify and prioritize novel drug targets in major depressive disorder (MDD), accelerating the Customer's drug discovery and clinical development program for this indication. The agreement also provides exclusive access to a target candidate. The MDD market was valued at more than $8 billion in 2025 and expected to grow at an average annual rate of nearly 5% to reach in excess of $11 billion by 2032, according to Stellar Market Research.

Completes end-to-end AI intelligence workflow product with an advanced AI decision tool that clearly defines drug target discovery and clinical trial strategies to build diversified, risk-balanced R&D portfolios Completes end-to-end AI intelligence workflow product with an advanced AI decision tool that clearly defines drug target discovery and clinical trial strategies to build diversified, risk-balanced R&D portfolios

March 27 webinar at 11 a.m. ET highlights launch of BullFrog AI's new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design March 27 webinar at 11 a.m. ET highlights launch of BullFrog AI's new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design

GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, announces the coming launch of a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design.

Company's bfLEAP® platform successfully identified treatment effect heterogeneity and possible early predictors of outcomes in pancreatic cancer in data to be presented at ASCO GI Company's bfLEAP® platform successfully identified treatment effect heterogeneity and possible early predictors of outcomes in pancreatic cancer in data to be presented at ASCO GI